Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries

Wong, Martin Cs; Goggins, William B.; Wang, Haoxiang; Fung, Francis; Leung, Colette; Wong, Samuel Yeung‐Shan; Ng, Chi Fai; Sung, Joseph J.Y.

doi:10.1016/j.eururo.2016.05.043

Cited by 430 publications

(336 citation statements)

References 19 publications

Supporting

Mentioning

318

Contrasting

Unclassified

Order By: Relevance

“…That the incidence rate of prostate cancer was greater in countries with higher GDPPC or more developed areas had been pointed out by many researchers (10)(11)(12)(13). The mortality rate was comparatively low in these countries, yet still higher than less developed regions (10,12,13). As for breast cancer, wealthier countries tended to have higher incidence rate (14,15), with the ASIR in more developed countries two times as high as in less developed countries (10).…”

Section: Introductionmentioning

confidence: 99%

“…Prostate cancer, which had the highest age-standardized incidence rate (ASIR) in all cancer types for men in more developed areas, was also the second most common cancer for men worldwide. It, together with breast cancer, the most common cancer and the leading cause of cancer death for women worldwide (10), was the two most studied cancer types. That the incidence rate of prostate cancer was greater in countries with higher GDPPC or more developed areas had been pointed out by many researchers (10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

“…It, together with breast cancer, the most common cancer and the leading cause of cancer death for women worldwide (10), was the two most studied cancer types. That the incidence rate of prostate cancer was greater in countries with higher GDPPC or more developed areas had been pointed out by many researchers (10)(11)(12)(13). The mortality rate was comparatively low in these countries, yet still higher than less developed regions (10,12,13).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Yang

Zheng

Zhang

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Objective: In this research, the patterns of cancer incidence and mortality in areas with different gross domestic product per capita (GDPPC) levels in China were explored, using data from population-based cancer registries in 2013, collected by the National Central Cancer Registry (NCCR).Methods: Data from 255 cancer registries were qualified and included in this analysis. Based on the GDPPC data of 2014, cities/counties were divided into 3 levels: high-, middle-and low-GDPPC areas, with 40,000 and 80,000 RMB per year as cut points. We calculated cancer incidences and mortalities in these three levels, stratified by gender and age group. The national population of the Fifth Census in 2000 and Segi's population were applied for age-standardized rates. Results:The crude incidence and mortality rates as well as age-standardized incidence rate (ASIR) showed positive associations with GDPPC level. The age-standardized mortality rate (ASMR) nevertheless showed a negative association with GDPPC level. The ASMR in high-, middle-and low-GDPPC areas was 103.12/100,000, 112.49/100,000 and 117.43/100,000, respectively. Lung cancer was by far the most common cancer in all three GDPPC levels. It was also the leading cause of cancer death, regardless of gender and GDPPC level. Negative associations with GDPPC level were found for the ASIRs of lung, stomach, esophageal and liver cancer, whereas colorectal and breast cancer showed positive associations. Except for breast cancer, the ASMRs of the other five cancers were always higher in middle-and low-GDPPC areas than in high-GDPPC areas. Conclusions:The economic development is one of the main factors of the heavy cancer burden on Chinese population. It would be reasonable to implement cancer control strategies referring to the local GDPPC level.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Yang

Zheng

Zhang

et al. 2017

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…Worldwide, PCa is the second most commonly diagnosed cancer and, according to the International Agency for Research on Cancer's GLOBOCAN 2012 (4) database, it is the fifth leading cause of cancer-associated mortality in men. The incidence of PCa is increasing worldwide, although there is a marked variation in its incidence among different regions (5). The clinical configuration of PCa has noticeably altered over the past few years.…”

Section: Introductionmentioning

confidence: 99%

HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method

et al. 2016

View full text Add to dashboard Cite

Abstract. Prostate cancer (PCa) is one of the most widespread malignancies in the world. The role of the human epidermal growth factor receptor 2 (HER2) in the pathogenesis and progression of human PCa remains poorly understood. In contradiction with breast cancer, studies on HER2 overexpression and gene amplification in PCa have produced varying results, although the HER2 oncogene has been implicated in the biology of numerous tumor types, and serves as a prognostic marker and therapeutic target in breast cancer. Technical challenges are considered the main reasons for data discrepancies. Amplification of the HER2 gene has previously been reported in PCa, in which it was associated with tumor progression. The present study aimed to evaluate the prevalence and clinical significance of HER2 amplification in PCa. A total of 32 biopsy samples obtained from human prostate adenocarcinomas were evaluated by chromogenic in situ hybridization (CISH) to determine the frequency of patients with HER2 gene amplifications. High copy numbers of HER2 were detected in 19 of the prostate tumors analyzed. The results of the present study suggested that, in patients without amplification of HER2, high levels of prostate-specific antigen or a high Gleason score were not significantly correlated with a high pathologic stage. Furthermore, amplification levels of the HER2 gene were directly associated with pathologic stage in patients with PCa. Therefore, the potential use of HER2 as a prognostic factor or therapeutic target for PCa warrants further study. IntroductionProstate cancer (PCa), a common non-skin, sex-limited cancer, is the second cause of cancer-associated mortality (after lung cancer) in the USA (1,2) and the second most prevalent cancer among Iranian men (3). Worldwide, PCa is the second most commonly diagnosed cancer and, according to the International Agency for Research on Cancer's GLOBOCAN 2012 (4) database, it is the fifth leading cause of cancer-associated mortality in men. The incidence of PCa is increasing worldwide, although there is a marked variation in its incidence among different regions (5). The clinical configuration of PCa has noticeably altered over the past few years. As a localized disease, it is easily treated by radical radiation therapy or a prostatectomy; however, if the tumor becomes malignant, it transforms into a life-threatening disease (6).The progression and application of novel high-resolution technologies has enhanced the detection of genomic alterations, enabling elucidation of the complex nature and heterogeneity of PCa (7). The differentiation of PCa tumors is typically based on the serum expression levels of prostate-specific antigen (PSA), although, in certain cases, PSA levels do not accurately reflect tumor burden (8). Previous studies have identified a number of genetic, epigenetic and environmental risk factors for PCa (9-11). Among them, genetic aberrations and chromosomal changes have been suggested to serve a significant role in the development and progression of PCa (12)

show abstract

“…Prostate cancer (PCa) is the second most common malignancy and a major cause of cancer deaths in men [1,2]. The increasing trend in PCa incidence reported over the last two decades, as well as differences in the geographic distribution of this value among different countries show a good parallelism with differences in the use of the Prostate Specific Antigen (PSA) assay for PCa diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges

Naponelli¹,

Ramazzina²,

Lenzi³

et al. 2017

Preprint

View full text Add to dashboard Cite

Green Tea Catechins (GTCs) are a family of chemically related compounds usually classified as antioxidant molecules. Epidemiological evidences, supported by interventional studies, highlighted a more than promising role for GTCs in human Prostate Cancer (PCa) chemoprevention.In the last decades many efforts have been made to gain new insights into the mechanism of action of GTCs. Now it is clear that GTCs anticancer action can no longer be simplistically limited to their direct antioxidant/pro-oxidant properties. Recent contributions to the advancement of knowledge in this field have shown that GTCs specifically interact with cellular targets including, cell surface receptors, lipid rafts and endoplasmic reticulum, modulate gene expression through direct effect on transcription factors or indirect epigenetic mechanisms, interfere with intracellular proteostasis at various levels. Many of the effects observed in vitro are dose and cell context dependent and take place at concentration that cannot be achieved in vivo.Poor intestinal absorption together with an extensive systemic and enteric metabolism influence GTCs bioavailability through still poor understood mechanisms. Recent efforts to develop delivery systems that increase GTCs overall bioavailability, by mean of biopolymeric nanoparticles, represent the main way to translate preclinical results in a real clinical scenario for PCa chemoprevention.

show abstract

Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries

Cited by 430 publications

References 19 publications

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

Comparison of cancer incidence and mortality in three GDP per capita levels in China, 2013

HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method

Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges

Contact Info

Product

Resources

About